SLB LIMITED/NV — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SLB LIMITED/NV filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $30.44B | Jan 24, 2018 |
| FY2017 | Dec 31, 2016 | $27.81B | Jan 24, 2018 |
| FY2017 | Dec 31, 2015 | $35.48B | Jan 24, 2018 |
| FY2016 | Dec 31, 2014 | $48.58B | Jan 25, 2017 |
| FY2015 | Dec 31, 2013 | $45.27B | Jan 27, 2016 |
| FY2014 | Dec 31, 2012 | $41.73B | Jan 29, 2015 |
| FY2013 | Dec 31, 2011 | $36.58B | Jan 31, 2014 |
| FY2012 | Dec 31, 2010 | $26.67B | Jan 31, 2013 |
| FY2011 | Dec 31, 2009 | $22.70B | Feb 1, 2012 |
| FY2010 | Dec 31, 2008 | $27.16B | Feb 4, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.71B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $36.29B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $33.14B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $28.09B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $22.93B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $23.60B | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $32.92B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $32.82B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $30.44B | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $27.81B | Jan 23, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.46B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $4.20B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $3.44B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $1.88B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | ($10.52B) | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | ($10.14B) | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $2.14B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | ($1.51B) | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | ($1.69B) | Jan 23, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $6.52B | Jan 24, 2024 |
| FY2023 | Dec 31, 2022 | $5.01B | Jan 24, 2024 |
| FY2023 | Dec 31, 2021 | $3.37B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $2.40B | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $3.98B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $4.19B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $3.92B | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $3.27B | Jan 23, 2019 |
| FY2017 | Dec 31, 2015 | $6.51B | Jan 24, 2018 |
| FY2016 | Dec 31, 2014 | $10.58B | Jan 25, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $709.00M | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $749.00M | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $711.00M | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $634.00M | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $554.00M | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $580.00M | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $717.00M | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $702.00M | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $787.00M | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $1.01B | Jan 23, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.49B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.60B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $6.64B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $3.72B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $4.65B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $2.94B | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $5.43B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $5.71B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $5.66B | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $6.26B | Jan 23, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $1.94B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.62B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $1.14B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $1.12B | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $1.72B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $2.16B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $2.11B | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $2.06B | Jan 23, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.87B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $48.94B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $47.96B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $43.14B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $41.51B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $42.43B | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | $56.31B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $70.51B | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | $71.99B | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | $77.96B | Jan 23, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.58B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $26.59B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $26.60B | Jan 22, 2025 |
| FY2023 | Dec 31, 2022 | $25.15B | Jan 24, 2024 |
| FY2022 | Dec 31, 2021 | $26.23B | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $29.95B | Jan 26, 2022 |
| FY2020 | Dec 31, 2019 | $32.14B | Jan 27, 2021 |
| FY2019 | Dec 31, 2018 | $33.92B | Jan 22, 2020 |
| FY2018 | Dec 31, 2017 | $34.73B | Jan 23, 2019 |
| FY2017 | Dec 31, 2016 | $36.43B | Jan 24, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.11B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $21.13B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $20.19B | Jan 22, 2025 |
| FY2023 | Dec 31, 2022 | $17.69B | Jan 24, 2024 |
| FY2022 | Dec 31, 2021 | $15.00B | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $12.07B | Jan 26, 2022 |
| FY2020 | Dec 31, 2019 | $23.76B | Jan 27, 2021 |
| FY2019 | Dec 31, 2018 | $36.16B | Jan 22, 2020 |
| FY2018 | Dec 31, 2017 | $36.84B | Jan 23, 2019 |
| FY2017 | Dec 31, 2016 | $41.08B | Jan 24, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.79B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $14.59B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | $14.08B | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | $12.98B | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | $12.99B | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | $12.98B | Jan 25, 2023 |
| FY2021 | Sep 30, 2020 | $12.97B | Jan 26, 2022 |
| FY2021 | Dec 31, 2019 | $16.04B | Jan 26, 2022 |
| FY2021 | Aug 31, 2019 | $25.00B | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | $24.93B | Jan 27, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.07B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | $16.40B | Jan 23, 2026 |
| FY2024 | Dec 31, 2023 | $13.50B | Jan 22, 2025 |
| FY2023 | Dec 31, 2022 | $10.72B | Jan 24, 2024 |
| FY2022 | Dec 31, 2021 | $8.20B | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | $7.02B | Jan 26, 2022 |
| FY2020 | Dec 31, 2019 | $18.75B | Jan 27, 2021 |
| FY2019 | Dec 31, 2018 | $31.66B | Jan 22, 2020 |
| FY2018 | Dec 31, 2017 | $32.19B | Jan 23, 2019 |
| FY2017 | Dec 31, 2016 | $36.47B | Jan 24, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $3.13B | Jan 29, 2015 |
| FY2014 | Dec 31, 2013 | $3.47B | Jan 29, 2015 |
| FY2014 | Dec 31, 2012 | $1.91B | Jan 29, 2015 |
| FY2014 | Dec 31, 2011 | $1.71B | Jan 29, 2015 |
| FY2013 | Dec 31, 2010 | $1.76B | Jan 31, 2014 |
| FY2012 | Dec 31, 2009 | $617.00M | Jan 31, 2013 |
| FY2011 | Dec 31, 2008 | $609.00M | Feb 1, 2012 |
| FY2010 | Dec 31, 2007 | $623.00M | Feb 4, 2011 |
| FY2009 | Dec 31, 2006 | $166.00M | Feb 5, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | (7) | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | (1) | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Jan 23, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Jan 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Jan 22, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Jan 24, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Jan 25, 2023 |
| FY2021 | Dec 31, 2019 | (7) | Jan 26, 2022 |
| FY2020 | Dec 31, 2018 | 1 | Jan 27, 2021 |
| FY2019 | Dec 31, 2017 | (1) | Jan 22, 2020 |
| FY2018 | Dec 31, 2016 | (1) | Jan 23, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.50B | Jan 23, 2026 |
| FY2025 | Dec 31, 2024 | 1.40B | Jan 23, 2026 |
| FY2025 | Dec 31, 2023 | 1.43B | Jan 23, 2026 |
| FY2025 | Dec 31, 2022 | 1.42B | Jan 23, 2026 |
| FY2022 | Dec 31, 2021 | 1.40B | Jan 25, 2023 |
| FY2021 | Dec 31, 2020 | 1.39B | Jan 26, 2022 |
| FY2020 | Dec 31, 2019 | 1.38B | Jan 27, 2021 |
| FY2019 | Dec 31, 2018 | 1.38B | Jan 22, 2020 |
| FY2018 | Dec 31, 2017 | 1.38B | Jan 23, 2019 |
| FY2017 | Dec 31, 2016 | 1.39B | Jan 24, 2018 |